Published in Prostate on August 01, 2005
NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03
Retracted Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev Res (Phila) (2009) 1.57
AHR signaling in prostate growth, morphogenesis, and disease. Biochem Pharmacol (2008) 1.51
Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res (2007) 1.29
Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther (2008) 1.27
Murine prostate cancer inhibition by dietary phytochemicals--curcumin and phenyethylisothiocyanate. Pharm Res (2008) 1.27
Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. Circulation (2007) 1.15
Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model. Pharm Res (2008) 1.14
The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol (2007) 1.13
Structural studies of NF-κB signaling. Cell Res (2010) 1.07
Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling. Carcinogenesis (2011) 1.05
The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target. Curr Cancer Drug Targets (2009) 1.03
Deregulation of FOXO3A during prostate cancer progression. Int J Oncol (2009) 1.02
Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis (2013) 1.01
Gadd45 proteins as critical signal transducers linking NF-kappaB to MAPK cascades. Curr Cancer Drug Targets (2009) 1.00
Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate (2013) 0.99
Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer (2007) 0.99
Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res (2011) 0.98
Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. Carcinogenesis (2008) 0.95
Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate (2013) 0.94
High-affinity interaction between IKKbeta and NEMO. Biochemistry (2008) 0.93
RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Ann N Y Acad Sci (2010) 0.93
Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α. PLoS One (2012) 0.92
Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate (2009) 0.90
Vinclozolin exposure in utero induces postpubertal prostatitis and reduces sperm production via a reversible hormone-regulated mechanism. Endocrinology (2010) 0.88
Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer. Cancers (Basel) (2011) 0.86
The Ron receptor promotes prostate tumor growth in the TRAMP mouse model. Oncogene (2011) 0.86
Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms. PLoS One (2012) 0.86
Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells. Mar Drugs (2013) 0.84
Apigenin blocks IKKα activation and suppresses prostate cancer progression. Oncotarget (2015) 0.84
Association between NFKB1 -94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis. Int J Genomics (2014) 0.83
Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia. Differentiation (2011) 0.82
Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells. Biochim Biophys Acta (2011) 0.81
NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.81
Novel targets for prostate cancer chemoprevention. Endocr Relat Cancer (2010) 0.80
Lobe-specific proteome changes in the dorsal-lateral and ventral prostate of TRAMP mice versus wild-type mice. Proteomics (2011) 0.80
Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis. Am J Pathol (2014) 0.79
α-Tocopheryl succinate induces apoptosis in erbB2-expressing breast cancer cell via NF-κB pathway. Acta Pharmacol Sin (2010) 0.77
PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal (2017) 0.75
Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer. Oncotarget (2016) 0.75
Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice. PLoS One (2015) 0.75
Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model. Oncotarget (2016) 0.75
Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. Oncotarget (2016) 0.75
ROS-independent Nrf2 activation in prostate cancer. Oncotarget (2017) 0.75
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet (2010) 6.84
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med (2012) 4.22
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells (2005) 3.16
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med (2006) 2.86
IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity (2008) 2.78
Choices. J Urol (2006) 2.01
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer (2007) 2.00
Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol (2002) 1.96
Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol (2007) 1.91
Splenic arterial interventions: anatomy, indications, technical considerations, and potential complications. Radiographics (2005) 1.85
Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics (2005) 1.85
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res (2004) 1.84
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 1.83
An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry (2011) 1.80
Management of airway in patients with laryngeal tumors. J Clin Anesth (2005) 1.80
Apigenin: a promising molecule for cancer prevention. Pharm Res (2010) 1.78
Role of sonography in the diagnosis of gallbladder perforation. J Clin Ultrasound (2002) 1.70
Benign intrascrotal lesions. J Urol (2004) 1.68
2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg (2013) 1.65
Restless legs syndrome in hemodialysis patients in India: a case controlled study. Sleep Med (2003) 1.64
Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene (2003) 1.62
CT-guided percutaneous fine-needle aspiration biopsy of small (< or =1-cm) pulmonary lesions. Radiology (2002) 1.59
A novel computer based expert decision making model for prostate cancer disease management. J Urol (2005) 1.59
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia (2004) 1.56
High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF-κB. Prostate (2011) 1.54
Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. Hum Pathol (2007) 1.52
IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. Int J Clin Exp Pathol (2011) 1.52
Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol (2012) 1.50
Renal metanephric adenoma. J Urol (2007) 1.46
A second mechanism for aluminum resistance in wheat relies on the constitutive efflux of citrate from roots. Plant Physiol (2008) 1.46
The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol (2006) 1.45
Anterior cruciate ligament reconstruction: MR imaging signs of anterior knee laxity in the presence of an intact graft. Radiology (2012) 1.44
Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol (2005) 1.43
Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett (2003) 1.42
Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J Agric Food Chem (2007) 1.41
Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest (2010) 1.40
Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol (2002) 1.40
Transhepatic portal vein embolization: anatomy, indications, and technical considerations. Radiographics (2002) 1.33
Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res (2007) 1.32
The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required? J Urol (2002) 1.31
Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol (2006) 1.30
Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle (2007) 1.30
Paratesticular liposarcoma. J Urol (2008) 1.29
Chamomile: A herbal medicine of the past with bright future. Mol Med Rep (2010) 1.29
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol (2013) 1.28
HIstome--a relational knowledgebase of human histone proteins and histone modifying enzymes. Nucleic Acids Res (2011) 1.25
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res (2009) 1.24
Loss of IRF-4-binding protein leads to the spontaneous development of systemic autoimmunity. J Clin Invest (2006) 1.24
Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res (2012) 1.24
Neuroendocrine carcinoma arising within a retroperitoneal mature teratoma. Ann R Coll Surg Engl (2010) 1.24
Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res (2004) 1.24
Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol (2006) 1.23
Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int J Cancer (2010) 1.22
Solanum nigrum: current perspectives on therapeutic properties. Altern Med Rev (2011) 1.22
The role of histone deacetylases in prostate cancer. Epigenetics (2008) 1.21
EZH2: not EZHY (easy) to deal. Mol Cancer Res (2014) 1.20
Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol (2002) 1.19
Embolization of spinal tumors: vascular anatomy, indications, and technique. Tech Vasc Interv Radiol (2011) 1.19
Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J Clin Microbiol (2008) 1.19
Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res (2007) 1.18
Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol (2005) 1.18
Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology (2004) 1.17
Assessing glomerular filtration rate in healthy Indian adults: a comparison of various prediction equations. J Nephrol (2005) 1.17
Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg (2012) 1.17
Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer (2005) 1.16
Germ cell origin of testicular carcinoid tumors. Clin Cancer Res (2008) 1.15
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol (2004) 1.15
Alkaliphilic bacteria: applications in industrial biotechnology. J Ind Microbiol Biotechnol (2011) 1.14
Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action. Carcinogenesis (2008) 1.14
Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol (2007) 1.13
Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model. Clin Cancer Res (2005) 1.13
Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem Biophys Res Commun (2006) 1.13
Near-infrared light triggers release of Paclitaxel from biodegradable microspheres: photothermal effect and enhanced antitumor activity. Small (2010) 1.12
Age at initiation & prevalence of tobacco use among school children in Noida, India: a cross-sectional questionnaire based survey. Indian J Med Res (2011) 1.12
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis (2011) 1.12
Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity. Life Sci (2009) 1.11
Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic Biol Med (2008) 1.11
Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol (2011) 1.11
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res (2012) 1.11
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res (2009) 1.11
Benign neoplasms of the epididymis. J Urol (2005) 1.09
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol (2006) 1.09
Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer (2005) 1.09
Arterioureteral fistulas: a clinical, diagnostic, and therapeutic dilemma. AJR Am J Roentgenol (2004) 1.09
Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther (2006) 1.09